- Home
- SANG vs LRMR Comparison
SANG vs LRMR Comparison
Compare SANG & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SANG
- LRMR
- Stock Information
- Founded
- SANG 1984
- LRMR N/A
- Country
- SANG Canada
- LRMR United States
- Employees
- SANG N/A
- LRMR N/A
- Industry
- SANG Computer Software: Programming Data Processing
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- SANG Technology
- LRMR Health Care
- Exchange
- SANG Nasdaq
- LRMR Nasdaq
- Market Cap
- SANG 189.6M
- LRMR 171.6M
- IPO Year
- SANG 2021
- LRMR N/A
- Fundamental
- Price
- SANG $5.74
- LRMR $3.25
- Analyst Decision
- SANG
- LRMR Strong Buy
- Analyst Count
- SANG 0
- LRMR 7
- Target Price
- SANG N/A
- LRMR $17.86
- AVG Volume (30 Days)
- SANG 4.8K
- LRMR 1.4M
- Earning Date
- SANG 05-08-2025
- LRMR 08-06-2025
- Dividend Yield
- SANG N/A
- LRMR N/A
- EPS Growth
- SANG N/A
- LRMR N/A
- EPS
- SANG N/A
- LRMR N/A
- Revenue
- SANG $238,264,000.00
- LRMR N/A
- Revenue This Year
- SANG N/A
- LRMR N/A
- Revenue Next Year
- SANG $2.91
- LRMR N/A
- P/E Ratio
- SANG N/A
- LRMR N/A
- Revenue Growth
- SANG N/A
- LRMR N/A
- 52 Week Low
- SANG $4.08
- LRMR $1.61
- 52 Week High
- SANG $7.99
- LRMR $11.20
- Technical
- Relative Strength Index (RSI)
- SANG 52.55
- LRMR 65.88
- Support Level
- SANG $5.55
- LRMR $2.22
- Resistance Level
- SANG $5.96
- LRMR $3.02
- Average True Range (ATR)
- SANG 0.14
- LRMR 0.33
- MACD
- SANG -0.02
- LRMR 0.03
- Stochastic Oscillator
- SANG 56.00
- LRMR 92.79
About SANG Sangoma Technologies Corporation
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.